Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.13 USD
Change Today -0.01 / -0.16%
Volume 102.7K
OCAT On Other Exchanges
As of 5:20 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

ocata therapeutics inc (OCAT) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/10/14 - $12.73
52 Week Low
06/13/14 - $4.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ocata therapeutics inc (OCAT) Related Bloomberg News

View More Bloomberg News

ocata therapeutics inc (OCAT) Related Businessweek News

No Related Businessweek News Found

ocata therapeutics inc (OCAT) Details

Ocata Therapeutics, Inc., a clinical stage biotechnology company, develops and commercializes regenerative ophthalmology therapeutics in the United States. The company is conducting various clinical trials for treating Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration, as well as pre-clinical trials for the treatment of other ocular disorders; and has pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory, and wound healing-related disorders. Its intellectual property portfolio includes pluripotent stem cell platforms, such as human embryonic stem cell and induced pluripotent stem cell platforms. The company’s intellectual property portfolio also comprises cell therapy research programs, such as ophthalmology programs, which include macular degeneration, photoreceptor progenitor, retinal ganglion cell progenitor, and corneal endothelial programs; and other programs, such as mesenchymal stem cell, neuroprotective biological, and platelet programs. As of February 11, 2015, it had 58 issued patents and 180 pending patent applications for the development of intellectual property portfolio. The company was formerly known as Advanced Cell Technology Inc. and changed its name to Ocata Therapeutics, Inc. in November 2014. Ocata Therapeutics, Inc. is headquartered in Marlborough, Massachusetts.

37 Employees
Last Reported Date: 03/16/15

ocata therapeutics inc (OCAT) Top Compensated Officers

Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $310.7K
Chief Scientific Officer
Total Annual Compensation: $586.2K
Compensation as of Fiscal Year 2013.

ocata therapeutics inc (OCAT) Key Developments

Ocata Therapeutics, Inc., Q4 2014 Earnings Call, Mar 12, 2015

Ocata Therapeutics, Inc., Q4 2014 Earnings Call, Mar 12, 2015

Ocata Therapeutics, Inc.(NasdaqGM:OCAT) added to NASDAQ Composite Index

Ocata Therapeutics, Inc. has been added to NASDAQ Composite Index.

Ocata Therapeutics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 09:20 AM

Ocata Therapeutics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 09:20 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Paul K. Wotton, Chief Executive Officer, President, Director and Member of Pricing Committee.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCAT:US $6.13 USD -0.01

OCAT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $2.86 USD -0.06
Cytori Therapeutics Inc $1.20 USD +0.01
Neuralstem Inc $1.95 USD -0.06
Organovo Holdings Inc $3.37 USD -0.29
Pluristem Therapeutics Inc $2.84 USD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation OCAT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,342.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,334.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCATA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at